Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy J. Wagers has a total of 423 co-authors. Here are the top co-authors by number of shared publications:

  • Kathleen A. Messemer

    Department of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA

    7 shared publications
  • Tata Nageswara Rao

    Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland

    6 shared publications
  • Kathleen Messemer

    Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA

    5 shared publications
  • Mohammadsharif Tabebordbar

    Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

    5 shared publications
  • Jill M. Goldstein

    Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA

    4 shared publications
  • Juhyun Oh

    Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Cambridge, MA 02138, USA

    4 shared publications

Latest Publications

  • Open Access

    In vivo Base Editing via Single Myotrophic Adeno-Associated Viruses in Dystrophic Mouse Muscle and Satellite Cells

    by Kuan-Hung Lin, Amy Lam, Amy J. Wagers

    Duchenne muscular dystrophy (DMD) is the most prevalent lethal X-linked neuromuscular disorder of childhood, caused by mutations in the Dmd gene that abrogate dystrophin expression. Although adeno-associated virus-mediated gene therapies hold tremendous promise for DMD treatment, their clinical applications have been constrained by dose-dependent vector toxicities. Here, we developed a single-vector adenine base editing strategy, delivered via a muscle-tropic adeno-associated virus (MyoAAV) at a clinically-feasible dose (4E13 VG/kg), to recode the pathogenic nonsense mutation into a benign missense mutation in mdx4cv DMD mouse model. This approach demonstrated efficacy across a broad age range (3 days to 6 months), but therapeutic outcomes were most effective in 3-week-old juvenile mice, which exhibited robust dystrophin restoration and improved muscle function. Notably, introduction of adenine base editors either earlier in neonatal or adult mice yielded substantially lower editing efficiencies, particularly in muscle satellite cells whose editing is essential to ensure durable rescue of dystrophin expression in growing and regenerating muscle. Collectively, these results demonstrate the therapeutic potential of single-vector adenine base editing for DMD and underscore the importance of recipient age and disease stage in achieving optimal treatment outcomes for this and other genetic muscle disorders.

  • Open Access

    In vivo base editing via single myotrophic adeno-associated viruses in dystrophic mouse muscle and satellite cells

    by Kuan-Hung Lin, Amy Lam, Samuel van Ooijen, Madeline Maier, Gracia Kassis, Regan Ellis, Kathleen Messemer, Jennifer Martin, Ramzi Khairallah, Amy Wagers

    Duchenne muscular dystrophy (DMD) is the most common, lethal X-linked neuromuscular disorder of childhood and is caused by mutations in the Dmd gene that disrupt dystrophin expression. Although adeno-associated virus-mediated gene therapies hold tremendous promise for DMD treatment, their clinical applications have been limited by dose-dependent vector and genome-level toxicities. Here, we developed and tested a single-vector adenine base editing strategy as a potentially safer genome editing approach to recode the pathogenic nonsense mutation into a benign missense mutation in mdx 4cv DMD mouse model. Delivered using a muscle-tropic adeno-associated virus (MyoAAV) at a clinically-feasible dose (4E13 VG/kg), this strategy enabled detectable molecular recoding of the mdx 4cv mutation in mice ranging in age from 3 days to 6 months. Yet, the overall efficiency and therapeutic impact of in vivo base editing with this system was highest in mice treated at the juvenile stage, with animals administered MyoAAV vectors at 3 weeks of age showing robust recovery of dystrophin expression and significant improvement in muscle contractile properties only one month later. Notably, introduction of adenine base editors either earlier in development, in neonatal mice, or later, in adulthood, yielded substantially lower editing efficiencies, particularly in muscle satellite cells whose editing is essential to ensure durable rescue of dystrophin expression in growing and regenerating muscle. Taken together, these results demonstrate the therapeutic potential of single-vector adenine base editing for DMD and underscore the importance of recipient age and disease stage in achieving optimal treatment outcomes for this and other genetic muscle disorders.

  • Open Access

    In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs

    by Alborz Karimzadeh, Rebekah Kim, Vivian Garcia, Michael Florea, Bryan L. Peacker, Shio Kobayashi, Drake Watkins, Kathleen Messemer, Jing Zeng, Daniel E. Bauer, et al.

    Hematopoietic stem cells (HSCs) are self-renewing, multipotent, and engraftable precursors of all blood cells. Efficient delivery of therapeutic gene products and gene editing machinery to correct disease-causing gene variants in endogenous HSCs while they remain in the body holds exciting potential to leverage HSC potency for the treatment of monogenic blood disorders. Toward this goal, we used adeno-associated virus (AAV) to deliver CRISPR guide RNAs (gRNAs) to edit HSC genomes in situ in Ai9;SpCas9-EGFP transgenic mice carrying a Cas9-activatable Lox-STOP-Lox-tdTomato reporter cassette together with a constitutive SpCas9-2A-EGFP. Using a variety of conditions and vector designs, we tested whether systemic administration to these mice of AAVs carrying SpCas9-compatible gRNAs designed to cut DNA upstream and downstream of the STOP cassette would induce tdTomato expression in HSCs. Our findings identify self-complementary AAVs (scAAVs) and increased ratio of guide to Cas9 as parameters facilitating higher editing efficiency. Of note, we find preserved multilineage output and engraftability of HSCs upon scAAV-gRNA editing. In an example application of this technology, we explore the potential for in situ HSC gene editing by dual AAV-CRISPR delivery and demonstrate robust gene modification, concurrent with induction of therapeutic fetal hemoglobin, in a sickle cell disease mouse model modified to express SpCas9. In summary, this work offers a sensitive and adaptable platform that allows robust modification of HSC genomes in situ.


  • Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke

    by Ori S. Cohen, Manisha Sinha, Yongting Wang, Tyler Daman, Pi-Chun Li, Catherine Deatherage, Berenice Charrez, Anish Deshpande, Samuel Jordan, Nyasha J. Makoni, et al.

    BACKGROUND: Stroke remains a leading cause of death and disability, underscoring the urgent need for treatments that enhance recovery. GDF11 (growth differentiation factor 11), a member of the TGF-β (transforming growth factor-β) superfamily, is a circulating protein involved in cellular development and tissue repair. GDF11 has gained attention for its potential regenerative properties in aging and disease contexts, making it a candidate for stroke recovery therapies. METHODS: The therapeutic benefits of rGDF11 (recombinant GDF11) were evaluated using a rat ischemic stroke model, in which focal cerebral infarcts were induced in 8- to 10-week-old young adult male Sprague-Dawley rats by permanently occluding the proximal right middle cerebral artery. Rats received single or multiple doses of rGDF11 (0.1–4 mg/kg) or vehicle from 24 to 72 hours post-injury. Sensorimotor functions were evaluated, and brain and serum samples were examined to determine the mechanisms of action and identify biomarkers, using immunofluorescence, target-specific ELISAs, and an aptamer-based proteomics platform. RESULTS: We confirmed rGDF11 activity in vitro and in established in vivo mouse models of cardiac hypertrophy and glucose metabolism and assessed the efficacy of rGDF11 treatment in 6 preclinical stroke studies using independent Contract Research Organizations, with all study animals and treatment groups blinded. All 6 studies revealed consistent improvement in sensorimotor outcomes with rGDF11. rGDF11-treated rats showed increased cortical vascularization and radial glia in the ventricular zone. Serum analysis revealed that rGDF11 caused dose-dependent decreases in CRP (C-reactive protein) and identified novel pharmacodynamic biomarkers and pathways associated with potential mechanisms of action of rGDF11. CONCLUSIONS: These results demonstrate that systemically delivered rGDF11 enhances neovascularization, reduces inflammation, promotes neurogenesis, and improves sensorimotor function post-injury in a rat model of ischemic stroke. More importantly, these data define an optimized and clinically feasible rGDF11 dosing regimen for therapeutic development in ischemic stroke and identify a panel of candidate pharmacodynamic and mechanistic biomarkers to support clinical translation.


  • Open Access

    Soluble RAGE enhances muscle regeneration after cryoinjury in aged and diseased mice

    by Naftali Horwitz, Michael Florea, K. C. Medha, Tina Liu, Vivian Garcia, Rebekah Kim, Amy Lam, Kathleen Messemer, Christopher Rios, Albert E. Almada, et al.

    The Receptor for Advanced Glycation End Products (RAGE), classically considered a mediator of acute and chronic inflammatory responses, has recently been implicated by genetic knockout studies as a regulator of skeletal muscle physiology during development and following acute injury. Yet, the role of its soluble isoform, soluble RAGE (sRAGE), in muscle regeneration remains relatively unexplored. To address this knowledge gap, Adeno-Associated Virus (AAV) mediated and genetic knockin supplementation strategies were developed to specifically assess the effects of changing levels of sRAGE on muscle regeneration. We evaluated general muscle physiology and histology, including central nucleation, and myofiber size. We found that acute induction of sRAGE in aged and atherosclerotic animals accelerates muscle repair after cryoinjury. Similarly, genetic modification of the endogenous Ager gene locus to favor production of sRAGE over transmembrane RAGE accelerates repair of cryo-damaged skeletal muscle. However, increasing sRAGE via AAV delivery or using our transgenic mouse lines had no impact on muscle repair in aged or diseased mice after barium chloride (BaCl2) injury. Together, these studies identify a unique muscle regulatory activity of sRAGE that is variable across injury models and may be targeted in a context-specific manner to alter the skeletal muscle microenvironment and boost muscle regenerative output.


  • Open Access

    Satellite cell-derived TRIM28 is pivotal for mechanical load- and injury-induced myogenesis

    by Kuan-Hung Lin, Jamie E Hibbert, Corey Gk Flynn, Jake L Lemens, Melissa M Torbey, Nathaniel D Steinert, Philip M Flejsierowicz, Kiley M Melka, Garrison T Lindley, Marcos Lares, et al.

    Satellite cells are skeletal muscle stem cells that contribute to postnatal muscle growth, and they endow skeletal muscle with the ability to regenerate after a severe injury. Here we discover that this myogenic potential of satellite cells requires a protein called tripartite motif-containing 28 (TRIM28). Interestingly, different from the role reported in a previous study based on C2C12 myoblasts, multiple lines of both in vitro and in vivo evidence reveal that the myogenic function of TRIM28 is not dependent on changes in the phosphorylation of its serine 473 residue. Moreover, the functions of TRIM28 are not mediated through the regulation of satellite cell proliferation or differentiation. Instead, our findings indicate that TRIM28 regulates the ability of satellite cells to progress through the process of fusion. Specifically, we discover that TRIM28 controls the expression of a fusogenic protein called myomixer and concomitant fusion pore formation. Collectively, the outcomes of this study expose the framework of a novel regulatory pathway that is essential for myogenesis.


  • Open Access

    Transplantation-based screen identifies inducers of muscle progenitor cell engraftment across vertebrate species

    by Sahar Tavakoli, Vivian Garcia, Eric Gähwiler, Isaac Adatto, Apoorva Rangan, Kathleen A. Messemer, Sara Ashrafi Kakhki, Song Yang, Victoria S. Chan, Margot E. Manning, et al.


  • Open Access

    Evidence for RNA or protein transport from somatic tissues to the male reproductive tract in mouse

    by Vera Rinaldi, Kathleen Messemer, Kathleen Desevin, Fengyun Sun, Bethany C Berry, Shweta Kukreja, Andrew R Tapper, Amy J Wagers, Oliver J Rando

    The development of tools to manipulate the mouse genome, including knockout and transgenic technology, has revolutionized our ability to explore gene function in mammals. Moreover, for genes that are expressed in multiple tissues or at multiple stages of development, the use of tissue-specific expression of the Cre recombinase allows gene function to be perturbed in specific cell types and/or at specific times. However, it is well known that putative tissue-specific promoters often drive unanticipated ‘off-target’ expression. In our efforts to explore the biology of the male reproductive tract, we unexpectedly found that expression of Cre in the central nervous system resulted in recombination in the epididymis, a tissue where sperm mature for ~1–2 weeks following the completion of testicular development. Remarkably, we not only observed reporter expression in the epididymis when Cre expression was driven from neuron-specific transgenes, but also when Cre expression in the brain was induced from an AAV vector carrying a Cre expression construct. A surprisingly wide range of Cre drivers – including six different neuronal promoters as well as the adipose-specific Adipoq Cre promoter – exhibited off-target recombination in the epididymis, with a subset of drivers also exhibiting unexpected activity in other tissues such as the reproductive accessory glands. Using a combination of parabiosis and serum transfer experiments, we find evidence supporting the hypothesis that Cre may be trafficked from its cell of origin to the epididymis through the circulatory system. Together, our findings should motivate caution when interpreting conditional alleles, and suggest the exciting possibility of inter-tissue RNA or protein trafficking in modulation of reproductive biology.


  • Open Access

    Transplantation-based screen uncovers inducers of muscle progenitor cell engraftment across vertebrate species

    by Sahar Tavakoli, Vivian Garcia, Eric Gahwiler, Isaac Adatto, Apoorva Rangan, Kathleen Messemer, Sara Ashrafi Kakhki, Song Yang, Victoria S Chan, Margot Manning, et al.

    Summary: Stem cell transplantation presents a potentially curative strategy for genetic disorders of skeletal muscle, but this approach is limited due to the deleterious effects of cell expansion in vitro and consequent poor engraftment efficiency. In an effort to overcome this limitation, we sought to identify molecular signals that enhance the myogenic activity of cultured muscle progenitors. Here, we report the development and application of a cross-species small molecule screening platform employing zebrafish and mouse, which enables rapid, direct evaluation of the effects of chemical compounds on the engraftment of transplanted muscle precursor cells. Using this system, we screened a library of bioactive lipids to identify those that could increase myogenic engraftment in vivo in zebrafish and mice. Two lipids, lysophosphatidic acid (LPA) and niflumic acid (NFA), are linked to activation of intracellular calcium ion flux, which showed conserved, dose-dependent and synergistic effects in promoting muscle engraftment across these vertebrate species.

  • Top Cited Papers

    Loss of epigenetic information as a cause of mammalian aging

    by Jae-Hyun Yang, Motoshi Hayano, Patrick T. Griffin, João A. Amorim, Michael S. Bonkowski, John K. Apostolides, Elias L. Salfati, Marco Blanchette, Elizabeth M. Munding, Mital Bhakta, et al.